The plan to expand Medicare coverage for popular GLP-1 drugs through the 'BALANCE' model starting in 2027 has been indefinitely postponed.
This delay was triggered by a simple mechanism built into the program's design: a lack of willing participants. The Centers for Medicare & Medicaid Services (CMS) stipulated that the model would only proceed if at least 80% of Part D plan providers volunteered to join. However, major insurers like UnitedHealth Group and CVS Health publicly expressed concerns or signaled non-participation just before the deadline, making it clear this critical threshold would not be met.
So, why were insurers so hesitant? The reasons are rooted in a complex mix of financial pressures and past experiences. First, the overall financial outlook for Medicare plans is uncertain. Proposed payment rate increases for 2027 are modest, squeezing insurer margins. Taking on the massive, unpredictable cost of covering GLP-1 drugs for millions of seniors felt like too great a gamble in this environment. Insurers prioritize certainty, and the BALANCE model offered anything but.
Second, insurers have been burned before. A previous pilot program called the VBID model was terminated in 2025 because it led to excessive spending. This recent failure made plans deeply skeptical of new, large-scale initiatives from CMS, demanding a higher risk premium to participate. Third, the potential demand for these drugs is enormous. In 2024, the FDA approved Wegovy for reducing cardiovascular risk, making many more Medicare beneficiaries eligible. This created fears of a cost explosion that insurers would be forced to absorb.
The market's reaction on April 21, 2026, was swift and logical. UnitedHealth's stock jumped over 8%, as investors breathed a sigh of relief that the company had dodged a major financial risk. Conversely, shares of GLP-1 makers Eli Lilly and Novo Nordisk fell 2-3%, as a significant future revenue stream was suddenly pushed further into the distance. This shows that for now, the practical question of 'who pays?' has overshadowed the medical argument for broader access.
- GLP-1 (Glucagon-like peptide-1) agonists: A class of drugs initially used for diabetes that are also highly effective for weight loss, such as Wegovy and Zepbound.
- Medicare Part D: The part of the U.S. Medicare program that provides prescription drug coverage to beneficiaries.
- CMS (Centers for Medicare & Medicaid Services): The U.S. federal agency that administers Medicare, Medicaid, and other health programs.